SCHEMBL18878192

SCHEMBL18878192

CN1CCCN2CCCC2C1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.38
HTR2B P41595 1/20 0.37
TMEM97 Q5BJF2 1/20 0.37
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TDP1 Q9NUW8 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HTR6 P50406 2/20 0.34
SIGMAR1 Q99720 4/20 0.34
CHRNA7 P36544 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
NPC1 O15118 1/20 0.34
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19337146 1.00 ALDH1A1 (0.39) ALDH1A1LMNAHTR2BTMEM97ATM
SCHEMBL18379019 0.95 ALDH1A1 (0.39) ALDH1A1LMNAHTR2BTMEM97ATM
SCHEMBL6639099 0.95 ALDH1A1 (0.39) ALDH1A1LMNAHTR2BTMEM97ATM
SCHEMBL18379098 0.95 ALDH1A1 (0.39) ALDH1A1LMNAHTR2BTMEM97ATM
SCHEMBL13330130 0.93 HTR6 (0.42) LMNAHTR6SIGMAR1MEN1KMT2A
SCHEMBL8435783 0.93 ALDH1A1 (0.38) ALDH1A1LMNAHTR2BTMEM97ATM
SCHEMBL13356 0.93 ALDH1A1 (0.38) ALDH1A1LMNAHTR2BTMEM97ATM
Hydrochloric Acid SCHEMBL27926198 0.93 ALDH1A1 (0.42) ALDH1A1LMNAHTR2BTMEM97ATM
SCHEMBL8435320 0.93 ALDH1A1 (0.38) ALDH1A1LMNAHTR2BTMEM97ATM
SCHEMBL7998551 0.91 LMNA (0.41) ALDH1A1LMNAL3MBTL1TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024115637-A1 CD93 INHIBITORS Universität Bern (CH) 2024-06-06 WO disclosed
WO-2022235699-A2 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2022-11-10 WO disclosed
WO-2022226667-A1 SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-11-03 WO disclosed
EP-3756464-A1 SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2020-12-30 EP disclosed
EP-3151669-B1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2020-10-28 EP disclosed
US-20200283398-A1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2020-09-10 US disclosed
WO-2020163554-A1 IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. (US) 2020-08-13 WO disclosed
US-20170144980-A1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2017-05-25 US disclosed
US-20170144980-A1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2017-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200283398-A1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI CYP51A1, DPM1, NOX1 ALDH1A1 1574/4885LMNA 4512/4885HTR2B 4467/4885
US-20170144980-A1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI CYP51A1, DPM1, NOX1 ALDH1A1 1574/4885LMNA 4512/4885HTR2B 4467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.